Radiation, targeted therapy, and immunotherapy for high-risk head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests if adding a targeted drug (nimotuzumab) and an immunotherapy (benmelstobart) after surgery and radiation can help prevent cancer from returning in patients with high-risk head and neck cancer who cannot take cisplatin chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a type of head and neck cancer that has been confirmed by biopsy and is locally advanced (stage III or IVB, but has not spread to other parts of your body)
- You have had surgery to remove the cancer, and the pathology showed at least one high-risk feature like cancer in the lymph nodes, close or positive margins, or multiple areas of nerve invasion
- You cannot take cisplatin chemotherapy because of age, kidney problems, hearing issues, or other medical reasons
- You are in good overall health (ECOG score 0 or 1) and have adequate blood, kidney, and liver function
- You have tumor tissue available for testing and are willing to provide informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three treatments—nimotuzumab (a targeted therapy), a PD-1 inhibitor (which boosts your immune system), and chemotherapy—followed by surgery for locally advanced head and neck squamous cell carcinoma. The goal is to shrink the tumor and improve survival.
This trial compares radiation therapy alone versus radiation therapy plus a targeted drug called nimotuzumab for people with advanced head and neck cancer who cannot take cisplatin chemotherapy. The goal is to see if adding nimotuzumab improves outcomes.
This trial tests whether combining the drug emactinib with chemotherapy and immunotherapy before surgery helps treat advanced head and neck cancer. It aims to shrink tumors and make surgery more effective.
This study tests a combination of two medications—cetuximab (a targeted antibody) and either pembrolizumab or finotonlimab (immunotherapies)—along with chemotherapy, for advanced head and neck cancer that has spread or come back. The goal is to see if this combination helps shrink tumors and improve survival compared to standard treatment.
This study tests two drugs (pertuzumab and lenvatinib) given together before surgery for advanced head and neck squamous cell carcinoma. The goal is to shrink the tumor and improve outcomes for patients who haven't received prior cancer treatment.
This study tests whether adding two different drugs (nimotuzumab and benmelstobart) to standard radiation therapy after surgery can help improve outcomes for people with intermediate-risk head and neck cancer. It looks at whether the combination slows cancer growth or reduces the chances of it coming back.
Hear when a new Postoperative Adjuvant Treatment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.